Big win for brand-name pharma companies in PTAB final decision
In a PTAB decision that brand-name pharmaceutical companies will celebrate, generic drug company Amneal has failed in its attempt to have three patents owned by Galderma cancelled – the first final written decision to involve an Orange Book-listed patent
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
